IBCI Enters into a Licensing and Distribution Agreement with Northeast
RELATED SYMBOLS: (IBCL)
ATLANTA, Nov 22, 2002 /PRNewswire-FirstCall via COMTEX/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL) is pleased to announce the signing of an exclusive licensing and distribution agreement with Bio Kleen, Inc. for the Marine and RV retail market in The United States. The distributor has placed an initial order for 10,000 pounds of our antimicrobial active ingredient, with potential additional orders in the near term. Their retailer is in the process of sub registering our product and plans to launch their new product line in January 2003. Under the new format of the distribution model, there are performance criteria that are required to be met; however, the program is not based on guaranteed revenue amounts. The program is based on a working relationship between the two companies to meet the objectives of both IBCI and Bio Kleen. Bio Kleen will provide IBCI status reports and plans on a regular basis, including projected volumes by quarter as part of the new distribution program. Ms. Deirdre Baker stated, "After months of negotiation we are very excited about the opportunity to work closely with Bio Kleen." Bio Kleen develops, markets, and distributes a number of products to the wastewater, remediation and health/pharmaceutical retail markets.
About, International BioChemical Industries, Inc.:
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date, BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water. Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com, or by calling Deirdre Baker at 1-770-925-3653.
Safe Harbor/Forward-looking Statements: Statements in this news release that are not historical are forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.